
Solid Biosciences (SLDB) Stock Forecast & Price Target
Solid Biosciences (SLDB) Analyst Ratings
Bulls say
Solid Biosciences is well positioned for success with their strong data package, unique safety profile, and potential approval from the FDA. The company may also benefit from changes in FDA leadership and has a promising pipeline for other genetic cardiac and neuromuscular diseases. With a market currently undervaluing the potential success of their treatments, Solid Biosciences's stock shows potential for growth and differentiation in the market.
Bears say
Solid Biosciences is currently focused on developing gene therapy treatments for neuromuscular and cardiac diseases. While the company has had some promising results in biomarker data, there are concerns about potential safety issues and the company's ability to successfully bring these treatments to market given the changing leadership at the FDA and the stringent regulatory requirements. Additionally, there is a significant financing risk as the company may need to seek partnerships or additional funding to support future commercialization and product development. Overall, the stock's current valuation appears to be discounting a lower probability of success, but if the upcoming functional data is positive, there could be significant upside potential.
This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Solid Biosciences (SLDB) Analyst Forecast & Price Prediction
Start investing in Solid Biosciences (SLDB)
Order type
Buy in
Order amount
Est. shares
0 shares